Form 4: Viridian Therapeutics CFO Seth Harmon Reports Stock Option and RSU Grants

Chief Financial Officer Seth Harmon reports the acquisition of stock options and restricted stock units in Viridian Therapeutics.

Summary

• Seth Harmon, CFO of Viridian Therapeutics, filed a Form 4 disclosing the grant of stock options and restricted stock units (RSUs).
• On March 3, 2025, Harmon was granted options to purchase 150,407 shares of common stock at an exercise price of $14.41.
• These options vest in 48 equal monthly installments starting from the grant date, contingent upon continued service.
• Harmon also received 25,068 RSUs, each representing a right to receive one share of common stock.
• These RSUs vest over a four-year period, with 25% vesting annually on each anniversary of the grant date, also subject to continued service.
• Following these transactions, Harmon directly owns 150,407 stock options and 25,068 RSUs.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grants are a standard practice and indicate confidence in the executive's continued contribution. There are no explicit negative implications.

Positives

• The grant of stock options and RSUs aligns the CFO's interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.
• The vesting schedule encourages continued service and commitment from the CFO.

Risks

• The value of the stock options and RSUs is dependent on the future performance of Viridian Therapeutics' stock price.
• If Harmon leaves the company before the options and RSUs fully vest, he will forfeit the unvested portion.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the equity grants suggest an expectation of continued service and contribution from the CFO.

Industry Context

Equity grants are a common practice in the biotechnology industry to attract and retain key executives, aligning their interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices in the biotech industry.
• Companies like Amgen, Gilead, and Regeneron routinely use equity-based compensation to incentivize their executives.
• The vesting schedules (monthly for options, annual for RSUs) are also typical in the industry, encouraging long-term commitment.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with the company's long-term success.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates